MaxCyte IncMXCT
Price$1.09

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $18.8M-15.3% YoYTTM through 30 Jun 2026
Net Income -$35.6MTTM through 30 Jun 2026
Free Cash Flow -$23.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin81.0%
EBITDA Margin-199.8%
Operating Margin-157.1%
Net Margin-189.3%

Returns

-26.0%ROE
-22.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio8.11x
Net Debt-$103Mnet cash position
Cash & Equivalents$15M

Quality Metrics

Altman Z-Score0.96
Piotroski F-Score3 / 9
FCF Margin-125.6%
Earnings-Beat Rate66.7%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $33M
Diluted EPS-$0.34TTM
'19'20'21'22'23'24'25
FY2025: $-0.42

Dividend

No dividend

Capital Allocation

R&D Spend$16.8M
Capex Intensity3.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.